COLLEGIUM PHARMACEUTICAL, INC — Director's Dealing 2017

Feb 14, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK: 0001267565
Period of Report: 2017-02-10

Reporting Person: Fleming Alison B (Chief Technology Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-01-27	Common Stock	A	1240	$10.08	Acquired	8451	Direct
2017-02-10	Common Stock	A	16250	—	Acquired	24701	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2017-02-10	Stock Option (Right to Purchase)	$15.27	A	32500	Acquired	2027-02-10	Common Stock (32500)	Direct

Footnotes

F1: These shares were acquired under the Collegium Pharmaceutical, Inc. 2015 Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

F2: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the restricted stock units vest on February 10, 2018, and the balance of the restricted stock units vest in equal installments every six months (in each case, rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer. The restricted stock units will be settled on each applicable vest date in shares of the issuer's common stock.

F3: The option vests and becomes exercisable over a four-year period commencing on February 10, 2017. Twenty-five percent (25%) of the option vests and becomes exercisable on February 10, 2018, and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) over the remaining three years of the four-year period, subject to the employee's continued service with the issuer.